Location History:
- Notre Dame, IN (US) (2015)
- St. Louis, MO (US) (2019)
- South Bend, IN (US) (2019 - 2023)
- Granger, IN (US) (2011 - 2024)
Company Filing History:
17 out of 368 
2 out of 579 
2 out of 1,584 
Years Active: 2011-2024
Title: The Innovative Contributions of Mayland Chang in Antibacterial Research
Introduction
Mayland Chang, a prolific inventor based in Granger, Indiana, has made significant strides in the field of antibacterial research. With a remarkable portfolio of 18 patents, Chang is dedicated to tackling some of the most pressing public health challenges, particularly those related to bacterial infections.
Latest Patents
His latest patents focus on compounds for the treatment of Clostridium difficile infection (CDI), a major public health concern that leads to approximately 14,000 deaths annually in the United States. CDI poses unique challenges due to its ability to produce spores that can remain dormant for years and toxins that damage the gut. Current treatments, such as vancomycin and metronidazole, fail to inhibit spore or toxin production, leading to recurrence in about 25% of patients. Chang’s research introduces oxadiazoles, which display effectiveness against highly virulent strains, including NAP1/027, known for increased toxin production. Notably, oxadiazole 2 is designed to achieve high concentrations in the gut while inhibiting vegetative cells, spores, and toxin production.
Additionally, Chang has developed compositions and methods of use for antibacterial drug combinations, specifically targeting resistant bacterial infections. These innovations could lead to more effective treatments for patients suffering from these persistent health threats.
Career Highlights
Throughout his career, Mayland Chang has served in academic and research roles at esteemed institutions such as the University of Notre Dame and Wayne State University. His commitment to advancing medical science through innovative research has positioned him as a key figure in the field of infectious diseases.
Collaborations
Chang's pioneering work has often involved collaboration with notable colleagues, including Shahriar Mobashery and Mijoon Lee. These partnerships have fostered a rich environment for innovative research and have contributed to the development of groundbreaking antibacterial therapies.
Conclusion
Mayland Chang's innovative contributions to the field of antibacterial research are substantial. By addressing critical health issues through his patents and collaborative efforts, Chang continues to play a vital role in the fight against resistant bacterial infections and evolving public health challenges. His work exemplifies the importance of innovation in improving healthcare outcomes and tackling antibiotic resistance.